| [Accepted Manuscript] Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. AC Gordon, AJ Mason, N Thirunavukkarasu, GD Perkins, M Cecconi, ... JAMA, 2016 | | 2016 |
| 293. Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organism: a prospective, randomised placebo-controlled feasibility trial-The … B Merrick, D Prossomariti, M Kertanegara, E Allen, C Sergaki, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 365, 2023 | | 2023 |
| 36 Diagnostic and Management Pathway for Sepsis M Singer, CS Deutschman, CW Seymour, M Shankar-Hari, D Annane, ... Basic Urological Management, 36, 2018 | | 2018 |
| 37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3) Brussels, Belgium. 21-24 March 2017 M Von Seth, L Hillered, A Otterbeck, K Hanslin, A Larsson, J Sjölin, ... Critical Care 21, 1-70, 2017 | 2 | 2017 |
| A comparison of mortality from sepsis in Brazil and England: the impact of heterogeneity in general and sepsis-specific patient characteristics OT Ranzani, M Shankar-Hari, DA Harrison, LS Rabello, JIF Salluh, ... Critical care medicine 47 (1), 76-84, 2019 | 22 | 2019 |
| A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis AG Laing, A Lorenc, I Del Molino Del Barrio, A Das, M Fish, L Monin, ... MedRxiv, 2020.06. 08.20125112, 2020 | 55 | 2020 |
| A dynamic COVID-19 immune signature includes associations with poor prognosis AG Laing, A Lorenc, I Del Molino Del Barrio, A Das, M Fish, L Monin, ... Nature medicine 26 (10), 1623-1635, 2020 | 964 | 2020 |
| A dynamic COVID-19 immune signature includes associations with poor prognosis (vol 26, pg 1623, 2020) AG Laing, A Lorenc, I del Molino del Barrio, A Das, M Fish, L Monin, ... Nature Medicine 26 (12), 1951-1951, 2020 | | 2020 |
| A dynamic COVID-19 immune signature includes associations with poor prognosis (vol 56, pg 512, 2020) AG Laing, A Lorenc, I del Molino del Barrio, A Das, M Fish, L Monin, ... NATURE MEDICINE 26 (10), 1663-1663, 2020 | | 2020 |
| A guide to immunotherapy for COVID-19 FL van de Veerdonk, E Giamarellos-Bourboulis, P Pickkers, L Derde, ... Nature medicine 28 (1), 39-50, 2022 | 286 | 2022 |
| A life-threatening sore throat masquerading as swine flu V Kahr, NA Barrett, M Shankar-Hari, H Slack, RL Preston, CN Fhogartaigh, ... The Lancet 375 (9713), 524, 2010 | 7 | 2010 |
| A living WHO guideline on drugs for covid-19 A Agarwal, BJ Hunt, M Stegemann, B Rochwerg, F Lamontagne, ... bmj 370, 2020 | 990* | 2020 |
| A living WHO guideline on drugs to prevent covid-19 F Lamontagne, M Stegemann, A Agarwal, T Agoritsas, R Siemieniuk, ... bmj 372, 2021 | 140 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 153 | 2021 |
| A proteomics-based assessment of inflammation signatures in endotoxemia SA Burnap, U Mayr, M Shankar-Hari, F Cuello, MR Thomas, AM Shah, ... Molecular & Cellular Proteomics 20, 2021 | 7 | 2021 |
| A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 T Wilkinson, A De Soyza, M Carroll, JD Chalmers, MG Crooks, G Griffiths, ... ERJ Open Research 9 (5), 2023 | 3 | 2023 |
| A second update on mapping the human genetic architecture of COVID-19 M Kanai, SJ Andrews, M Cordioli, C Stevens, BM Neale, M Daly, A Ganna, ... Nature 621 (7977), E7-E26, 2023 | 25 | 2023 |
| Acceptance and transfer to a regional severe respiratory failure and veno‐venous extracorporeal membrane oxygenation (ECMO) service: predictors and outcomes SA Gillon, K Rowland, M Shankar‐Hari, L Camporota, GW Glover, ... Anaesthesia 73 (2), 177-186, 2018 | 22 | 2018 |
| ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in … T Wilkinson, R Dixon, C Page, M Carroll, G Griffiths, LP Ho, A De Soyza, ... Trials 21, 1-3, 2020 | 70 | 2020 |
| Accounting for heterogeneity in relative treatment effects for use in cost-effectiveness models and value-of-information analyses NJ Welton, MO Soares, S Palmer, AE Ades, D Harrison, M Shankar-Hari, ... Medical Decision Making 35 (5), 608-621, 2015 | 24 | 2015 |
